A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say

A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.

By Alexandra Pecci • Sept. 12, 2023

In advocates’ ongoing push for superbug funding, ‘$6 billion is nothing’

The PASTEUR Act is likely heading for another legislative blow, but advocates say they see a future for the mechanism to fund the battle against antimicrobial resistance.

By Karissa Waddick • Sept. 8, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Pharma faces a slew of leadership shakeups

Biogen, Sanofi, Bristol Myers Squibb and more have all recently announced major executive changes.

By Karissa Waddick • Sept. 7, 2023

‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride

Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.

By Michael Gibney • Sept. 7, 2023

Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery

Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.

By Alexandra Pecci • Sept. 6, 2023

Hope sputters for emerging anti-TIGIT drug class

Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.

By Kelly Bilodeau • Sept. 5, 2023

Roz Brewer announces sudden departure as CEO of Walgreens

The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.

By Meagan Parrish • Sept. 1, 2023

Lawmakers are already gunning for more dramatic drug pricing reforms

Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.

By Karissa Waddick • Aug. 31, 2023

Finding the right flu vaccine is hard. Getting people to take it is harder.

Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.

By Michael Gibney • Aug. 30, 2023

Medicare named the first 10 drugs up for negotiation. Now what?

The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

By Karissa Waddick • Aug. 30, 2023

5 of the best places to work in pharma, according to employees

Work-life balance is one major common denominator among the top-ranked pharma employers on Glassdoor.

By Alexandra Pecci • Aug. 29, 2023

Are weight loss drugs a win for the global economy?

As Novo Nordisk’s drug Wegovy sways Denmark’s economy, we're examining wider implications for the weight loss market. 

By Karissa Waddick • Aug. 28, 2023

Why pharma isn’t done tackling migraines

In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options. 

By Kelly Bilodeau • Aug. 28, 2023

Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’

FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages. 

By Karissa Waddick • Aug. 25, 2023

‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.

By Michael Gibney • Aug. 24, 2023

How an AstraZeneca exec is leading the charge in the next immuno-oncology era

The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.

By Michael Gibney • Aug. 17, 2023

A leading Democrat reveals how his mental health struggles shape his policy approach

Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.

By Karissa Waddick • Aug. 17, 2023

Woman of the Week: Novartis’ Christy Siegel

The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.

By Taren Grom and Meagan Parrish • Aug. 15, 2023

Demand for weight loss drugs soars to nearly half of Americans

Drugs like the buzzy Ozempic are high on consumers’ radar — but lofty barriers to access remain.

By Alexandra Pecci • Aug. 15, 2023

Pharma’s rare disease rush

Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?

By Meagan Parrish , Karissa Waddick • Aug. 14, 2023

5 minutes with — Lundbeck CEO Dr. Deborah Dunsire

The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.

By Meagan Parrish • Aug. 11, 2023

Biogen’s Reata acquisition reflects biopharma’s inevitable M&A, IPO return to growth

July’s announcement from the beleaguered drugmaker signals the kind of shift the industry could see more of as M&A and IPOs tick up once again.

By Michael Gibney • Aug. 10, 2023

What pharma companies are getting wrong about drug repositioning

Children’s Tumor Foundation president Annette Bakker is working to teach the industry the crucial difference between drug repurposing and drug repositioning.

By Alexandra Pecci • Aug. 9, 2023

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

By Karissa Waddick • Aug. 7, 2023

A pioneering approach to biotherapeutic antibody discovery

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous.

By Kimberley Bryon-Dodd, PhD • Aug. 7, 2023